Juana Oramás

894 total citations
20 papers, 341 citations indexed

About

Juana Oramás is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Juana Oramás has authored 20 papers receiving a total of 341 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Juana Oramás's work include Lung Cancer Treatments and Mutations (9 papers), Colorectal Cancer Treatments and Studies (5 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Juana Oramás is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Colorectal Cancer Treatments and Studies (5 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Juana Oramás collaborates with scholars based in Spain and United States. Juana Oramás's co-authors include Norberto Batista, Emilio González‐Reimers, Francisco Santolaria, Antonio Milena, Maria José Menezes Brito, Marta Llanos, Lucio Díaz‐Flores, Manuel Dómine, Bartomeu Massutí and Ana Laura Ortega Granados and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Treatment Reviews and JAIDS Journal of Acquired Immune Deficiency Syndromes.

In The Last Decade

Juana Oramás

19 papers receiving 322 citations

Peers

Juana Oramás
Richard A. Lutes United States
C Grohé Germany
Linde M. Morsink Netherlands
Orren Beaty United States
H. van den Berg Netherlands
Yanna Dou China
Lobna R. Ezz El Arab Egypt
Jonathan Tucci United States
C. Haberl Germany
Richard A. Lutes United States
Juana Oramás
Citations per year, relative to Juana Oramás Juana Oramás (= 1×) peers Richard A. Lutes

Countries citing papers authored by Juana Oramás

Since Specialization
Citations

This map shows the geographic impact of Juana Oramás's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juana Oramás with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juana Oramás more than expected).

Fields of papers citing papers by Juana Oramás

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juana Oramás. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juana Oramás. The network helps show where Juana Oramás may publish in the future.

Co-authorship network of co-authors of Juana Oramás

This figure shows the co-authorship network connecting the top 25 collaborators of Juana Oramás. A scholar is included among the top collaborators of Juana Oramás based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juana Oramás. Juana Oramás is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Martín-Liberal, Juan, Iván Márquez‐Rodas, Ainara Soria, et al.. (2025). Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases. Cancer Treatment Reviews. 133. 102886–102886. 1 indexed citations
2.
Ochenduszko, Sebastián, Guillermo Crespo, Juana Oramás, et al.. (2021). Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice. OncoTargets and Therapy. Volume 14. 5345–5352. 5 indexed citations
3.
Provencio, Mariano, Enric Carcereny, Delvys Rodríguez‐Abreu, et al.. (2019). Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study). Translational Lung Cancer Research. 8(4). 461–475. 43 indexed citations
4.
Granados, Ana Laura Ortega, et al.. (2019). Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer. Anticancer Research. 39(3). 1317–1328. 2 indexed citations
5.
Dómine, Manuel, Bartomeu Massutí, Javier Puente, et al.. (2019). Observational Prospective Study to Determine the Evolution of the Symptomatic Profile of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients and Its Relation to the Control of the Disease. Advances in Therapy. 36(6). 1497–1508. 3 indexed citations
6.
García‐García, Francisco, Atocha Romero, Enric Carcereny, et al.. (2019). Sex is a strong prognostic factor for overall survival in advanced non small cell lung cancer patients and should be considered for survival rates estimations.. Journal of Clinical Oncology. 37(15_suppl). e20580–e20580. 1 indexed citations
7.
Gutiérrez, Fernando R., et al.. (2016). Hematological toxicity of carboplatin for gynecological cancer according to body mass index. European Journal of Clinical Pharmacology. 72(9). 1083–1089. 8 indexed citations
8.
Massutí, Bartomeu, Eloísa Jantus‐Lewintre, Delvys Rodríguez‐Abreu, et al.. (2014). ANGIOMET: Analysis of the correlations between angiogenic markers and outcome in patients (p) with advanced nonsquamous NSCLC (NS-NSCLC) treated with carboplatin, paclitaxel, and bevacizumab (CPB).. Journal of Clinical Oncology. 32(15_suppl). e19014–e19014. 1 indexed citations
9.
Provencio, Mariano, Manuel Cobo, Sergio Vázquez‐Estévez, et al.. (2010). Analysis of prognostic factors in patients with advanced non-small cell lung cancer (NSCLC) who are candidates to receive a second-line treatment.. Journal of Clinical Oncology. 28(15_suppl). e18109–e18109. 1 indexed citations
10.
Alberola, Vicente, Óscar Gallego, Guillermo López-Vivanco, et al.. (2007). P3-061: Erlotinib as single agent in elderly patients (p) with advanced or metastatic NSCLC. Journal of Thoracic Oncology. 2(8). S703–S704. 2 indexed citations
11.
Llanos, Marta, et al.. (2007). Bone mineral density in women with non-metastatic breast cancer: Effect of intravenous bisphosphonates given before adjuvant therapies. Journal of Clinical Oncology. 25(18_suppl). 11038–11038.
12.
Alberola, Vicente, Óscar Gallego, Guillermo López-Vivanco, et al.. (2007). Improvement in symptoms and quality of life (QoL) for patients (p) with non-small cell lung cancer (NSCLC) treated with erloninib: TargeT study. Journal of Clinical Oncology. 25(18_suppl). 18140–18140. 1 indexed citations
13.
Maestu, I., Dolores Isla, Pedro Diz Dios, et al.. (2007). Vinorelbine (VRB) plus gemcitabine (GEM) as first-line treatment for elderly patients (p) with advanced non-small cell lung cancer (NSCLC): Molecular correlates. Journal of Clinical Oncology. 25(18_suppl). 18040–18040. 1 indexed citations
14.
Sánchez‐Rovira, Pedro, et al.. (2006). Phase II study of capecitabine (X) in combination with vinorelbine (N) in patients (pts) with pretreated metastatic breast cancer (MBC). Journal of Clinical Oncology. 24(18_suppl). 10693–10693. 1 indexed citations
15.
Sánchez‐Rovira, Pedro, et al.. (2004). Phase II study with the combination of capecitabine (C) and vinorelbine (V) in metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes. Journal of Clinical Oncology. 22(14_suppl). 748–748. 2 indexed citations
16.
Sánchez‐Rovira, Pedro, et al.. (2004). Phase II study with the combination of capecitabine (C) and vinorelbine (V) in metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes. Journal of Clinical Oncology. 22(14_suppl). 748–748. 4 indexed citations
17.
18.
Santolaria, Francisco, Norberto Batista, Antonio Milena, et al.. (1999). CYTOKINE LEVELS (IL-6 AND IFN-γ), ACUTE PHASE RESPONSE AND NUTRITIONAL STATUS AS PROGNOSTIC FACTORS IN LUNG CANCER. Cytokine. 11(1). 80–86. 184 indexed citations
19.
Valls, María Remedios Alemán, et al.. (1999). MALIGNANT PLASMA CELL TUMOR WITH HIV INFECTION IN A 30 YEAR OLD MAN. JAIDS Journal of Acquired Immune Deficiency Syndromes. 21(1). A26–A26. 1 indexed citations
20.
Santolaria, Francisco, Emilio González‐Reimers, Juana Oramás, et al.. (1994). Short-term Prognostic Value of Subjective Nutritional Assessment in General Medical Patients. 4(3). 287–295. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard A. Lutes Breakdown of academic impact, for papers by C Grohé Breakdown of academic impact, for papers by Linde M. Morsink Breakdown of academic impact, for papers by Orren Beaty Breakdown of academic impact, for papers by H. van den Berg Breakdown of academic impact, for papers by Yanna Dou Breakdown of academic impact, for papers by Lobna R. Ezz El Arab Breakdown of academic impact, for papers by Jonathan Tucci Breakdown of academic impact, for papers by C. Haberl
Rankless by CCL
2026